NCT07139353

Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma: A Prospective, Multicenter, Open-label, Phase Ib/II Clinical Study

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 54 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of linperlisib combined with chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma

Conditions

• Peripheral T Cells Lymphoma (PTCL)

Interventions

Type	Name	Description
DRUG	Linperlisib	Linperlisib: 80 mg or 60 mg, po, qd (phase Ib); RP2D (phase II)
DRUG	Chidamide	Chidamide: 20mg, po, biw

Timeline

• Start date: 2025-09-15
• Primary completion: 2027-09-01
• Completion: 2029-09-01
• First posted: 2025-08-24
• Last updated: 2025-08-24